№ files_lp_4_process_2_57391
File format: docx Character count: 1384 File size: 31 KB
A survey designed to collect data on the use of adjuvant chemotherapy and radiotherapy for incompletely resected early stage Non-small Cell Lung Cancer (NSCLC) in Europe, conducted by the Young Oncologist Committee of ESMO.
Year: 2012
Region / City: Europe / Vienna
Theme: Lung Cancer, Oncology
Document Type: Survey
Organization / Institution: European Society for Medical Oncology (ESMO)
Author: Dr. Raffaele Califano
Target Audience: Medical Oncologists, Radiation Oncologists
Period of Action: Deadline end of February 2012
Approval Date: N/A
Date of Changes: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Prognostic value of desmoplastic growth patterns in resected hepatocellular carcinoma
Year: 2022
Region / City: Oulu, Vaasa, Jyväskylä, Finland; Solna, Sweden
Topic: Hepatocellular carcinoma, Prognostic markers
Document type: Research Article
Institution: Oulu University Hospital, Karolinska Institutet
Authors: Niklas Sarelin, Valtteri Kairaluoma, Juha Saarnio, Joonas H. Kauppila, Jan Böhm, Heikki Huhta, Juha P. Väyrynen, Olli Helminen
Target audience: Medical researchers, oncologists, pathologists
Period of validity: N/A
Approval date: 2022
Modification date: N/A
Supplementary Materials for Neoantigens heterogeneity as a prognostic marker in patients with resected intrahepatic cholangiocarcinoma
Year: 2026
Region / City: Not specified
Topic: Cancer research
Document type: Supplementary Materials
Institution: Not specified
Authors: Jianzhen Lin, Bo Hu, Yang Shi, Jiaqian Wang, Xu Yang, Weikang Hu, Xiaobo Yang, Xin Lu, Xinting Sang, Zhibo Gao, Ruibin Xi, Haitao Zhao
Target audience: Medical researchers, Oncologists
Period of validity: Not specified
Approval date: Not specified
Date of amendments: Not specified
Note: Contextual description
AMIVANTAMAB and Lazertinib PBS Listing Submission for First-Line Treatment of EGFRm NSCLC
Year: 2025
Region / city: Australia
Subject: Oncology, Pharmaceutical Submission
Document Type: Pharmaceutical Benefits Scheme (PBS) Submission
Organ / Institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: JANSSEN-CILAG PTY LTD
Target Audience: Medical practitioners, healthcare professionals
Period of validity: Ongoing
Approval Date: Pending
Date of modifications: N/A
NHS Genomic Medicine Service ctDNA Testing for NSCLC and Breast Cancer Provision for 2025/26
Year: 2025
Region / City: North West NHS GMS region
Topic: ctDNA testing for NSCLC and breast cancer
Document Type: Notification
Organization: NHS England
Author: Genomics Unit
Target Audience: NHS Trusts
Period of Action: 2025/26 financial year
Approval Date: 7 November 2025
Date of Changes: N/A
Context: Notification regarding the continuation and expansion of ctDNA testing for lung and breast cancer in the North West NHS region for the 2025/26 financial year.
Osimertinib for Stage IB to IIIA Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation as Adjuvant Therapy
Year: 2021
Region / city: Australia
Topic: Oncology / Pharmaceutical
Document Type: Submission
Agency: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: AstraZeneca Pty Ltd
Target Audience: Medical professionals, regulatory authorities
Validity Period: 2021-2026
Approval Date: 20 April 2021
Modification Date: Not specified
Supplementary materials for the manuscript “Radiomic detection of EGFR mutations in NSCLC”
Year: 2023
Region / city: Not specified
Topic: Radiomics, Machine learning, EGFR mutation detection
Document type: Supplementary material
Author: Not specified
Target audience: Researchers, Medical professionals
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Contextual description: Supplementary material for a scientific manuscript discussing the radiomic detection of EGFR mutations in non-small cell lung cancer (NSCLC) using machine learning techniques.
Clinical Outcomes and Progression Patterns of EGFR-Mutant NSCLC Patients Following Third-Generation EGFR-TKIs and Immuno-Based Therapies (2018–2023)
Year: 2018–2023
Institution: Jiangsu Cancer Center, Affiliated Cancer Hospital of Nanjing Medical University
Study Type: Retrospective clinical study
Patient Population: NSCLC patients with EGFR mutations
Treatment Modalities: Third-generation EGFR-TKIs, immunotherapy-based regimens
Endpoints: PFS1, PFS2, PFS1+PFS2, OS, ORR, DCR
Analysis Methods: Kaplan-Meier survival analysis, Cox proportional hazards models, LASSO regression
Imaging Assessment: Enhanced CT, RECIST v1.1 criteria
Ethics Approval: KY-2025-013
Significant Predictors: Previous immunotherapy sensitivity, tumor burden, selected clinical variables
Data Collection Period: November 1, 2018 – November 1, 2023
Supplementary Figures on CHK1 Inhibition and DNA Polymerase Interactions in Human NSCLC and Colorectal Cancer Cell Lines
Year: Not specified
Scientific field: Molecular biology; cancer research
Research topic: CHK1 inhibition and DNA polymerase interaction in cancer cells
Document type: Supplementary figures and experimental data description
Biological materials: Human NSCLC and colorectal cancer cell lines
Cell lines: A549, SW620, NCI-H1975, Calu-6, HCT116, RKO, NCI-H460, HBEC3-KT
Key genes / proteins: CHK1, POLA1, POLE, POLE2, RPA32, H2AX, GAPDH
Experimental methods: SRB assay, siRNA knockdown, western blot analysis, fluorescence microscopy, linear regression analysis
Chemical compounds: SRA737, MK-8776, aphidicolin, gemcitabine, CD437, DMSO
Statistical analysis: Student’s t-test, Chou–Talalay method, linear regression
Measured outcomes: GI50 values, cell proliferation, protein expression levels, replication stress markers, phosphorylation of RPA32, H2AX foci formation
Experimental design: Drug treatment and gene knockdown assays in cultured human cancer cell lines
Sample size: Biological replicates typically n ≥ 2–3
Purpose: Analysis of synthetic lethality and drug interaction effects involving CHK1 inhibition and DNA polymerase activity
Submission for listing of selpercatinib (Retevmo®) for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC)
Year: 2023
Region / city: Australia
Theme: Oncology, Pharmacology
Document type: Pharmaceutical submission
Institution: ELI LILLY AUSTRALIA PTY LTD
Author: Not specified
Target audience: Medical professionals, health policy makers
Effective period: Not specified
Approval date: 3 July 2023
Amendment date: Not specified
Topics: Incompletely Resected NSCLC